Emerging Infectious Diseases (Aug 2021)

Costs and Outcomes of Integrated Human African Trypanosomiasis Surveillance System Using Rapid Diagnostic Tests, Democratic Republic of the Congo

  • Rian Snijders,
  • Alain Fukinsia,
  • Yves Claeys,
  • Epco Hasker,
  • Alain Mpanya,
  • Erick Miaka,
  • Filip Meheus,
  • Marleen Boelaert

DOI
https://doi.org/10.3201/eid2708.202399
Journal volume & issue
Vol. 27, no. 8
pp. 2144 – 2153

Abstract

Read online

We integrated sleeping sickness case detection into the primary healthcare system in 2 health districts in the Democratic Republic of the Congo. We replaced a less field-friendly serologic test with a rapid diagnostic test, which was followed up by human African trypanosomiasis microscopic testing, and used a mixed costing methodology to estimate costs from a healthcare provider perspective. We screened a total of 18,225 persons and identified 27 new cases. Average financial cost (i.e., actual expenditures) was US $6.70/person screened and $4,464/case diagnosed and treated. Average economic cost (i.e., value of resources foregone that could have been used for other purposes) was $9.40/person screened and $6,138/case diagnosed and treated. Our study shows that integrating sleeping sickness surveillance into the primary healthcare system is feasible and highlights challenges in completing the diagnostic referral process and developing a context-adapted diagnostic algorithm for the large-scale implementation of this strategy in a sustainable and low-cost manner.

Keywords